Literature DB >> 23281436

Shades of gray between large B-cell lymphomas and Hodgkin lymphomas: differential diagnosis and biological implications.

Nancy L Harris1.   

Abstract

Hodgkin lymphomas (HLs) are neoplasms of large B cells. Two types are recognized: nodular lymphocyte predominant HL (NLPHL) and classical HL (CHL). In both types, there may be morphological and possibly biological overlap with large B-cell lymphomas (LBCLs) of non-HL types. These include nodular sclerosis CHL and primary mediastinal large B-cell lymphoma; CHL rich in lymphocytes and NLPHL; and NLPHL and T-cell/histiocyte-rich LBCL. This review covers the defining features of each of these diseases, the borderlines between them, and strategies for differential diagnosis.

Entities:  

Mesh:

Year:  2013        PMID: 23281436     DOI: 10.1038/modpathol.2012.182

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  11 in total

1.  Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.

Authors:  Michael Crump; Sattva S Neelapu; Umar Farooq; Eric Van Den Neste; John Kuruvilla; Jason Westin; Brian K Link; Annette Hay; James R Cerhan; Liting Zhu; Sami Boussetta; Lei Feng; Matthew J Maurer; Lynn Navale; Jeff Wiezorek; William Y Go; Christian Gisselbrecht
Journal:  Blood       Date:  2017-08-03       Impact factor: 22.113

2.  A Historical Tale of Two Lymphomas: Part I: Hodgkin lymphoma.

Authors:  Ritu Lakhtakia; Ikram Burney
Journal:  Sultan Qaboos Univ Med J       Date:  2015-05-28

3.  PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.

Authors:  Benjamin J Chen; Bjoern Chapuy; Jing Ouyang; Heather H Sun; Margaretha G M Roemer; Mina L Xu; Hongbo Yu; Christopher D M Fletcher; Gordon J Freeman; Margaret A Shipp; Scott J Rodig
Journal:  Clin Cancer Res       Date:  2013-05-14       Impact factor: 12.531

4.  Minimal Treatment of Low-Risk, Pediatric Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the Children's Oncology Group.

Authors:  Burton E Appel; Lu Chen; Allen B Buxton; Robert E Hutchison; David C Hodgson; Peter F Ehrlich; Louis S Constine; Cindy L Schwartz
Journal:  J Clin Oncol       Date:  2016-05-16       Impact factor: 44.544

5.  CD20 Over-Expression in Hodgkin-Reed-Sternberg Cells of Classical Hodgkin Lymphoma: the Neglected Quest.

Authors:  Daniel Benharroch; Karen Nalbandyan; Irina Lazarev
Journal:  J Cancer       Date:  2015-09-15       Impact factor: 4.207

6.  Primary mediastinal large B-cell lymphoma.

Authors:  Anna Dabrowska-Iwanicka; Jan A Walewski
Journal:  Curr Hematol Malig Rep       Date:  2014-09       Impact factor: 3.952

7.  Nodular Lymphocyte Predominant Hodgkin Lymphoma versus T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: A Diagnostic Challenge.

Authors:  Anton V Rets; Susan R S Gottesman
Journal:  Case Rep Pathol       Date:  2014-07-07

8.  Fatal necrotizing angiotropic Epstein-Barr virus-negative large B-cell lymphoma: a case report with unusual clinicopathological features in-between lymphomatoid granulomatosis and T-cell/histiocyte-rich large B-cell lymphoma.

Authors:  Attilio Olivieri; Elena Sabattini; Gaia Goteri; Silvia Trappolini; Francesco Saraceni; Arduino Samorì; Guido Gini; Pietro Leoni; Jacopo Olivieri; Stefano A Pileri
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

9.  Biostable ssDNA aptamers specific for Hodgkin lymphoma.

Authors:  Parag Parekh; Sanchit Kamble; Nianxi Zhao; Zihua Zeng; Jianguo Wen; Bin Yuan; Youli Zu
Journal:  Sensors (Basel)       Date:  2013-10-25       Impact factor: 3.576

10.  FOXO1 downregulation contributes to the oncogenic program of primary mediastinal B-cell lymphoma.

Authors:  Linka Xie; Olga Ritz; Frank Leithäuser; Hanfeng Guan; Johanna Färbinger; Clarissa D Weitzer; Franziska Gehringer; Silke Bruederlein; Karlheinz Holzmann; Marion J Vogel; Peter Möller; Thomas Wirth; Alexey Ushmorov
Journal:  Oncotarget       Date:  2014-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.